Luer

Becton Dickinson (BD) and ICU Medical Lead the Global Needleless Connector Market to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Other Manufacturing, Medical Supplies, Health, Medical Devices, Chemicals, Plastics, Manufacturing, Other Health, Male, Luer, Government of Saskatchewan, Research, BD (company), National League Championship Series, NLC, ICU Medical, Needleless connector, Growth, Hospital, BD, Video game, Pharmaceutical industry

The global needleless connector market showcased impressive expansion in 2023, reaching a total value of $1.33 billion.

Key Points: 
  • The global needleless connector market showcased impressive expansion in 2023, reaching a total value of $1.33 billion.
  • Remarkably, the global needleless connector market is currently led by two key players, Becton Dickinson (BD) and ICU Medical.
  • Market Leaders: Becton Dickinson (BD) and ICU Medical have emerged as dominant forces in the global needleless connector market.
  • Becton Dickinson (BD): In 2023, Becton Dickinson (BD) solidified its position as the global leader in the Needleless Connector (NLC) market.

Global Blood Transfusion Set Market Expected to Rebound with 3.0% CAGR, Reaching $591 Million by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Health, Other Health, Male, IV, Prevalence, ICU Medical, Pump, Baxter, Cancer, Luer, Domination, Research, BD (company), Blood transfusion, Chronic, BD, Medical device, Pharmaceutical industry, Alaris

In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.

Key Points: 
  • In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.
  • Currently, market leaders in the global blood transfusion set market include Becton Dickinson (BD), Baxter, and ICU Medical.
  • Rebound Expected: The global blood transfusion set market is projected to rebound with a CAGR of 3.0%, reaching a valuation of $591 million, following a 3.5% decline in 2023.
  • Dominant Players: Key players such as Becton Dickinson (BD), Baxter, and ICU Medical currently dominate the global blood transfusion set market.

Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

Retrieved on: 
Wednesday, July 12, 2023
Newell Brands, Partnership, AptarGroup, Luer, Research, Injection, Sharps, Growth, Pharmaceutical industry, Centor criteria, Gerresheimer

NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

Key Points: 
  • Mr. Scheu will be instrumental in leading Sharps’ marketing initiatives as the Company advances from research and development to commercial revenue.
  • His initial focus will be leading sales efforts around Sharps’ commercial-ready Securegard®, a disposable smart safety syringe product offering with multiple configurations.
  • The qualification agreement will allow for the opportunity to create secondary sales agreements with additional key hospital networks, which Mr. Scheu will oversee.
  • Through Mr. Scheu’s deep expertise in plastics operations and sales, he will play an integral role in supporting the partnership with Nephron Pharmaceuticals.

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retrieved on: 
Wednesday, December 28, 2022
Medical Supplies, Medical Devices, Health, Hospitals, Other Health, General Health, Bloodstream infections, Injury, Transport, Syringe, Injection, Risk, NYSE, Safety, Luer, Maintenance, RVP, IV, Medical device, Retractable hardtop

Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.

Key Points: 
  • Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.
  • The dividends cover the period beginning October 1, 2022 through December 31, 2022.
  • The dividends will be paid on January 20, 2023 to shareholders of record as of the close of business on January 10, 2023.
  • Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle.

Retractable Technologies, Inc. Reports Stock Price Anomalies

Retrieved on: 
Thursday, December 15, 2022
General Health, Health, Medical Supplies, Medical Devices, IV, Syringe, NYSE, Injury, Common stock, Commission, Luer, RVP, Risk, Bloodstream infections, Injection, Anomaly, Retractions in academic publishing

Retractable Technologies, Inc. (NYSE American: RVP) issues this press release to express the Companys concern regarding stock price anomalies in its Common Stock and disclose actions taken to date.

Key Points: 
  • Retractable Technologies, Inc. (NYSE American: RVP) issues this press release to express the Companys concern regarding stock price anomalies in its Common Stock and disclose actions taken to date.
  • This in-depth analysis, costing the Company over $600 thousand, confirmed that there were statistically significant anomalies in the markets reaction to the Companys positive disclosures, meaning that the Companys stock price would often react negatively or in a statistically insignificant way following positive earnings reports and press releases.
  • Retractable manufactures and markets VanishPoint and Patient Safe safety medical products and the EasyPoint needle.
  • The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections.

Retractable Technologies, Inc. Results for the Periods Ended September 30, 2022

Retrieved on: 
Monday, November 14, 2022
General Health, Medical Devices, Hospitals, Health, Medical Supplies, Injection, Injury, Government, Luer, Safety, IV, Transport, Maintenance, Bloodstream infections, Syringe, Comparison, Risk, Medical device, Music, Forming (metalworking), Security (finance), Retractable hardtop

Retractable reports the following results of operations for the three and nine months ended September 30, 2022 and 2021, respectively.

Key Points: 
  • Retractable reports the following results of operations for the three and nine months ended September 30, 2022 and 2021, respectively.
  • Comparison of Three Months Ended September 30, 2022 and September 30, 2021
    Domestic sales accounted for 39.9% and 93.7% of the revenues for the three months ended September 30, 2022 and 2021, respectively.
  • Domestic unit sales were 29.0% of total unit sales for the three months ended September 30, 2022. International revenues increased approximately 507.4% predominantly due to international vaccination campaigns.
  • Domestic unit sales were 40.7% of total unit sales for the nine months ended September 30, 2022.

The Worldwide Colorectal Procedure Industry is Expected to Reach $29.5 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Surgery, Oncology, Other Health, Prevalence, Amazon, Food, Risk, GI, Cade, Colorectal cancer, PAP, Google Images, Artificial intelligence, COVID-19, Bleeding, US Foods, ECHELON, Polyp (medicine), Safety, Large intestine, Colonoscopy, Endoscopy, Stoma, Clinical trial, Luer, IDA, Physician, Patient, Growth, Crohn's disease, Colorectal surgery, Blood, FDA, CAGR, Pharmaceutical industry, Medical device, Medicare, Medtronic, Ethicon Inc.

The global colorectal procedure market is projected to reach US$ 29,550.98 million by 2028 from US$ 12,496.49 million in 2021.

Key Points: 
  • The global colorectal procedure market is projected to reach US$ 29,550.98 million by 2028 from US$ 12,496.49 million in 2021.
  • It is expected to register a CAGR of 13.1% from 2021 to 2028.
  • The increasing prevalence of colorectal cancer and new product launches drive the growth of colorectal procedure.
  • The colorectal procedural market players focus on launching new products to expand their geographic reach and enhance capacities to cater to a large customer base.

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retrieved on: 
Friday, September 30, 2022
General Health, Other Health, Hospitals, Health, Medical Supplies, Injection, Injury, Safety, IV, Risk, NYSE, Luer, U.S. Securities and Exchange Commission, RVP, Private Securities Litigation Reform Act, Maintenance, Forward-looking statement, Transport, Board of directors, Syringe, Board, Bloodstream infections, Medical device, Retractable hardtop

Retractable Technologies, Inc. (Retractable) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.

Key Points: 
  • Retractable Technologies, Inc. (Retractable) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.
  • The dividends cover the period beginning July 1, 2022 through September 30, 2022.
  • The dividends will be paid on October 21, 2022 to shareholders of record as of the close of business on October 11, 2022.
  • Retractable manufactures and markets VanishPoint and Patient Safe safety medical products and the EasyPoint needle.

Global Intravenous Solutions Market to Surpass US$ 15,906.0 Million by 2030 - Coherent Market Insights

Retrieved on: 
Friday, August 19, 2022
Diarrhea, B. Braun, Solution, Life, IV, Baxter International, Blood, Systematic review, US, Food, Luer, Teva Pharmaceuticals, Investment, Pfizer, S.A, Prevalence, Vomiting, CAGR, FDA, Norovirus, LLC, Gastroenteritis, Microorganism, Risk, Analysis, Acquisition, Growth, Meta-analysis, Fine chemical, Medical device, Pharmaceutical industry

SEATTLE, Aug. 19, 2022 /PRNewswire/ --According to Coherent Market Insights, the global intravenous solutions market is estimated to be valued at US$ 9,907.8 million in 2022 and is expected to exhibit a CAGR of 6.1 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, Aug. 19, 2022 /PRNewswire/ --According to Coherent Market Insights, the global intravenous solutions market is estimated to be valued at US$ 9,907.8 million in 2022 and is expected to exhibit a CAGR of 6.1 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Intravenous Solutions Market:
    Major players operating in market are focusing on adopting growth strategies such acquisitions and product launch, which is expected to drive the market growth over the forecast period.
  • This in turn is expected to drive growth of the global intravenous solutions market .
  • Among region, North America is expected to hold a dominant position in the global intravenous solutions market over the forecast period, owing to increasing number of inorganic growth strategies by key market players in the region.

Retractable Technologies, Inc. Results for the Periods Ended June 30, 2022

Retrieved on: 
Monday, August 15, 2022
General Health, Other Health, Hospitals, Health, Medical Supplies, U.S. Securities and Exchange Commission, Risk, Income, Injection, Forward-looking statement, IV, Private Securities Litigation Reform Act, Luer, Government, Injury, Syringe, COVID-19, Safety, Comparison, Maintenance, Bloodstream infections, Online gambling, Animal, Music, Health insurance, Security (finance), Renewable energy, Retractable hardtop

Retractable reports the following results of operations for the three and six months ended June 30, 2022 and 2021, respectively.

Key Points: 
  • Retractable reports the following results of operations for the three and six months ended June 30, 2022 and 2021, respectively.
  • Comparison of Three Months Ended June 30, 2022 and June 30, 2021
    Domestic sales accounted for 66.7% and 94.3% of the revenues for the three months ended June 30, 2022 and 2021, respectively.
  • Domestic unit sales were 51.4% of total unit sales for the three months ended June 30, 2022. International revenues increased approximately 97.5% predominately due to international vaccination campaigns.
  • Domestic unit sales were 46.5% of total unit sales for the six months ended June 30, 2022.